U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C28H31N3O6
Molecular Weight 505.5633
Optical Activity ( + / - )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BENIDIPINE

SMILES

CC1=C([C@@]([H])(c2cccc(c2)N(=O)=O)C(=C(C)N1)C(=O)O[C@]3([H])CCCN(Cc4ccccc4)C3)C(=O)OC

InChI

InChIKey=QZVNQOLPLYWLHQ-ZEQKJWHPSA-N
InChI=1S/C28H31N3O6/c1-18-24(27(32)36-3)26(21-11-7-12-22(15-21)31(34)35)25(19(2)29-18)28(33)37-23-13-8-14-30(17-23)16-20-9-5-4-6-10-20/h4-7,9-12,15,23,26,29H,8,13-14,16-17H2,1-3H3/t23-,26-/m1/s1

HIDE SMILES / InChI

Molecular Formula C28H31N3O6
Molecular Weight 505.5633
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Benidipine is an orally triple L-, T-, and N-type calcium channel blocker for the treatment of hypertension and angina pectoris synthesized and developed by Kyowa Hakko Kogyo Co., Ltd. Benidipine, approved in Japan in November 1991, has become one of the three best selling CCBs and is highly useful as a potent, long-lasting antihypertensive and antianginal agent.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CONIEL

Approved Use

CONIEL is a calcium channel blocker and extensive clinical testing has demonstrated the sustained efficacy and effectiveness of this agent. A large body of evidence including clinical data and analyses demonstrates that CONIEL protects the heart, kidneys and brain from the effects of hypertension and angina pectoris.

Launch Date

688867200000
Primary
CONIEL

Approved Use

CONIEL is a calcium channel blocker and extensive clinical testing has demonstrated the sustained efficacy and effectiveness of this agent. A large body of evidence including clinical data and analyses demonstrates that CONIEL protects the heart, kidneys and brain from the effects of hypertension and angina pectoris.

Launch Date

688867200000
PubMed

PubMed

TitleDatePubMed
[Effects of benidipine hydrochloride (Coniel) on blood pressure, heart rate and plasma norepinephrine concentration in spontaneously hypertensive rats].
1999 May
Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions.
2000 Feb-Mar
Interaction of digoxin with antihypertensive drugs via MDR1.
2002 Feb 15
A case of exercise-induced acute renal failure in a patient with idiopathic renal hypouricemia developed during antihypertensive therapy with losartan and trichlormethiazide.
2003 Jun
Benidipine, a long-acting calcium channel blocker, inhibits cardiac remodeling in pressure-overloaded mice.
2005 Mar 1
Subdepressor dose of benidipine ameliorates diabetic cardiac remodeling accompanied by normalization of upregulated endothelin system in rats.
2006 May
Renal-protective effect of T-and L-type calcium channel blockers in hypertensive patients: an Amlodipine-to-Benidipine Changeover (ABC) study.
2007 Sep
Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R.
2008 Apr 28
Patents

Patents

Sample Use Guides

Orally, 4 mg/day
Route of Administration: Oral
The oocytes expressing select Ca channels were cultured for 2 to 4 days and then subjected to electrophysiological measurement. The oocytes were placed in a small chamber perfused with extracellular solution , and Ba2+ currents through expressed channels were measured by the two-microelectrode voltageclamp method. The experimental chamber was 0.5 ml in volume, and it was perfused continuously with the extracellular solution. Typically, oocytes were clamped at a holding potential of 2100, 280, or 260 mV and depolarized to 110 mV for 200 ms every 15 s. Microelectrodes were filled with 3 M KCl, and those showing a resistance of 0.5 to 1.2 VM were used. Benidine was evaluated in concentration range of 0.1 - 100 uM, and demonstrated blocking effect with IC50 of 0.7 uM.
Substance Class Chemical
Created
by admin
on Sat Jun 26 04:28:28 UTC 2021
Edited
by admin
on Sat Jun 26 04:28:28 UTC 2021
Record UNII
4G9T91JS7E
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BENIDIPINE
INN   MI   WHO-DD  
INN  
Official Name English
BENIDIPINE [MI]
Common Name English
(+/-)-(R*)-3-((R*)-1-BENZYL-3-PIPERIDYL) METHYL 1,4-DIHYDRO-2,6-DIMETHYL-4-(M-NITROPHENYL)-3,5-PYRIDINEDICARBOXYLATE
Systematic Name English
BENIDIPINE [WHO-DD]
Common Name English
(+/-)-2,6-DIMETHYL-4-(3-NITROPHENYL)-1,4-DIHYDROPYRIDINE-3,5-DICARBOXYLIC ACID-3-(1-BENZYL-3-PIPERIDYL) ESTER-5-METHYL ESTER
Common Name English
BENIDIPINE [INN]
Common Name English
(4R)-REL-1,4-DIHYDRO-2,6-DIMETHYL-4-(3-NITROPHENYL)-3,5-PYRIDINEDICARBOXYLIC ACID METHYL (3R)-1-(PHENYLMETHYL)-3-PIPERIDINYL ESTER
Common Name English
Classification Tree Code System Code
WHO-VATC QC08CA15
Created by admin on Sat Jun 26 04:28:28 UTC 2021 , Edited by admin on Sat Jun 26 04:28:28 UTC 2021
NCI_THESAURUS C333
Created by admin on Sat Jun 26 04:28:28 UTC 2021 , Edited by admin on Sat Jun 26 04:28:28 UTC 2021
WHO-ATC C08CA15
Created by admin on Sat Jun 26 04:28:28 UTC 2021 , Edited by admin on Sat Jun 26 04:28:28 UTC 2021
Code System Code Type Description
NCI_THESAURUS
C81680
Created by admin on Sat Jun 26 04:28:28 UTC 2021 , Edited by admin on Sat Jun 26 04:28:28 UTC 2021
PRIMARY
CAS
105979-17-7
Created by admin on Sat Jun 26 04:28:28 UTC 2021 , Edited by admin on Sat Jun 26 04:28:28 UTC 2021
PRIMARY
FDA UNII
4G9T91JS7E
Created by admin on Sat Jun 26 04:28:28 UTC 2021 , Edited by admin on Sat Jun 26 04:28:28 UTC 2021
PRIMARY
INN
6137
Created by admin on Sat Jun 26 04:28:28 UTC 2021 , Edited by admin on Sat Jun 26 04:28:28 UTC 2021
PRIMARY
DRUG CENTRAL
3880
Created by admin on Sat Jun 26 04:28:28 UTC 2021 , Edited by admin on Sat Jun 26 04:28:28 UTC 2021
PRIMARY
EPA CompTox
105979-17-7
Created by admin on Sat Jun 26 04:28:28 UTC 2021 , Edited by admin on Sat Jun 26 04:28:28 UTC 2021
PRIMARY
MERCK INDEX
M2315
Created by admin on Sat Jun 26 04:28:28 UTC 2021 , Edited by admin on Sat Jun 26 04:28:28 UTC 2021
PRIMARY Merck Index
MESH
C061004
Created by admin on Sat Jun 26 04:28:28 UTC 2021 , Edited by admin on Sat Jun 26 04:28:28 UTC 2021
PRIMARY
EVMPD
SUB05719MIG
Created by admin on Sat Jun 26 04:28:28 UTC 2021 , Edited by admin on Sat Jun 26 04:28:28 UTC 2021
PRIMARY
PUBCHEM
656668
Created by admin on Sat Jun 26 04:28:28 UTC 2021 , Edited by admin on Sat Jun 26 04:28:28 UTC 2021
PRIMARY
ChEMBL
CHEMBL2218858
Created by admin on Sat Jun 26 04:28:28 UTC 2021 , Edited by admin on Sat Jun 26 04:28:28 UTC 2021
PRIMARY
WIKIPEDIA
BENIDIPINE
Created by admin on Sat Jun 26 04:28:28 UTC 2021 , Edited by admin on Sat Jun 26 04:28:28 UTC 2021
PRIMARY
DRUG BANK
DB09231
Created by admin on Sat Jun 26 04:28:28 UTC 2021 , Edited by admin on Sat Jun 26 04:28:28 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
MAJOR
BINDER->LIGAND
BINDING
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE -> PARENT
IN VITRO
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC ORAL ADMINISTRATION